• Something wrong with this record ?

The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/-) and TP53(-/-) cells

AJ. Willis, R. Indra, LE. Wohak, O. Sozeri, K. Feser, I. Mrizova, DH. Phillips, M. Stiborova, VM. Arlt,

. 2018 ; 398-399 (-) : 1-12. [pub] 20180219

Language English Country Ireland

Document type Journal Article, Research Support, Non-U.S. Gov't

Polycyclic aromatic hydrocarbons such as benzo[a]pyrene (BaP) can induce cytochrome P450 1A1 (CYP1A1) via a p53-dependent mechanism. The effect of different p53-activating chemotherapeutic drugs on CYP1A1 expression, and the resultant effect on BaP metabolism, was investigated in a panel of isogenic human colorectal HCT116 cells with differing TP53 status. Cells that were TP53(+/+), TP53(+/-) or TP53(-/-) were treated for up to 48 h with 60 μM cisplatin, 50 μM etoposide or 5 μM ellipticine, each of which caused high p53 induction at moderate cytotoxicity (60-80% cell viability). We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect. Co-incubation experiments with the drugs and 2.5 μM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression. Further, whereas cisplatin and etoposide had virtually no influence on CYP1A1-catalysed BaP metabolism, ellipticine treatment strongly inhibited BaP bioactivation. Our results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone. These results could be relevant for smokers, who are exposed to increased levels of BaP, when prescribing chemotherapeutic drugs. Beside gene-environment interactions, more considerations should be given to potential drug-environment interactions during chemotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000905
003      
CZ-PrNML
005      
20190121113320.0
007      
ta
008      
190107s2018 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.tox.2018.02.006 $2 doi
035    __
$a (PubMed)29471073
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Willis, Alexandra J $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
245    14
$a The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/-) and TP53(-/-) cells / $c AJ. Willis, R. Indra, LE. Wohak, O. Sozeri, K. Feser, I. Mrizova, DH. Phillips, M. Stiborova, VM. Arlt,
520    9_
$a Polycyclic aromatic hydrocarbons such as benzo[a]pyrene (BaP) can induce cytochrome P450 1A1 (CYP1A1) via a p53-dependent mechanism. The effect of different p53-activating chemotherapeutic drugs on CYP1A1 expression, and the resultant effect on BaP metabolism, was investigated in a panel of isogenic human colorectal HCT116 cells with differing TP53 status. Cells that were TP53(+/+), TP53(+/-) or TP53(-/-) were treated for up to 48 h with 60 μM cisplatin, 50 μM etoposide or 5 μM ellipticine, each of which caused high p53 induction at moderate cytotoxicity (60-80% cell viability). We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect. Co-incubation experiments with the drugs and 2.5 μM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression. Further, whereas cisplatin and etoposide had virtually no influence on CYP1A1-catalysed BaP metabolism, ellipticine treatment strongly inhibited BaP bioactivation. Our results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone. These results could be relevant for smokers, who are exposed to increased levels of BaP, when prescribing chemotherapeutic drugs. Beside gene-environment interactions, more considerations should be given to potential drug-environment interactions during chemotherapy.
650    _2
$a metabolická aktivace $7 D065767
650    _2
$a benzopyren $x farmakokinetika $x farmakologie $7 D001564
650    _2
$a karcinogeny $x farmakokinetika $x farmakologie $7 D002273
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cisplatina $x farmakologie $7 D002945
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D015179
650    _2
$a cytochrom P-450 CYP1A1 $x biosyntéza $x metabolismus $7 D019363
650    _2
$a cytochrom P-450 CYP3A $x biosyntéza $x metabolismus $7 D051544
650    _2
$a adukty DNA $x metabolismus $7 D018736
650    _2
$a poškození DNA $7 D004249
650    _2
$a elipticiny $x farmakokinetika $x farmakologie $7 D004611
650    _2
$a enzymová indukce $x účinky léků $7 D004790
650    _2
$a etoposid $x farmakologie $7 D005047
650    _2
$a geny p53 $7 D016158
650    _2
$a HCT116 buňky $7 D045325
650    _2
$a lidé $7 D006801
650    _2
$a nádorový supresorový protein p53 $x nedostatek $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Indra, Radek $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
700    1_
$a Wohak, Laura E $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
700    1_
$a Sozeri, Osman $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
700    1_
$a Feser, Kerstin $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
700    1_
$a Mrizova, Iveta $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
700    1_
$a Phillips, David H $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom; NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England, London, 150 Stamford Street, London SE1 9NH, United Kingdom.
700    1_
$a Stiborova, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
700    1_
$a Arlt, Volker M $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom; NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England, London, 150 Stamford Street, London SE1 9NH, United Kingdom. Electronic address: volker.arlt@kcl.ac.uk.
773    0_
$w MED00004533 $t Toxicology $x 1879-3185 $g Roč. 398-399, č. - (2018), s. 1-12
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29471073 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190121113538 $b ABA008
999    __
$a ok $b bmc $g 1364882 $s 1039028
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 398-399 $c - $d 1-12 $e 20180219 $i 1879-3185 $m Toxicology $n Toxicology $x MED00004533
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...